Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by Zacks Research to Strong-Buy Rating

Zacks Research upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a hold rating to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

Several other research analysts have also recently weighed in on the company. JPMorgan Chase & Co. upgraded Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a research note on Monday, December 8th. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Finally, Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, January 6th. Three equities research analysts have rated the stock with a Strong Buy rating and four have assigned a Buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy”.

Bayer Aktiengesellschaft Trading Up 1.4%

OTCMKTS:BAYRY opened at $12.68 on Tuesday. The stock has a market cap of $49.16 billion, a price-to-earnings ratio of -140.87, a PEG ratio of 4.74 and a beta of 0.66. The company has a quick ratio of 0.71, a current ratio of 1.14 and a debt-to-equity ratio of 1.10. The company’s 50 day moving average price is $10.27 and its 200-day moving average price is $8.80. Bayer Aktiengesellschaft has a 52 week low of $5.30 and a 52 week high of $13.00.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.